Protocol Library - Altai Oncology Software

Altai Protocol Library

Our protocol library curated since 2015 with over 1,000 protocols forms the basis of all our Oncology software solutions

Over 1,000 cancer treatment protocols

Medical Oncology, Hematology, Bone Marrow Transplantation

With administration details, lab parameters, indications, and summarized references

Updated monthly to include latest approvals and major papers

Reviewed by Medical Oncologists and Hematologists

Soft Tissue Sarcoma

New Indication: Atezolizumab for Advanced Alveolar Soft Part Sarcoma

Ulas D. Bayraktar, MD

GastroEsophageal Cancer

New Reference: Pembrolizumab with Chemotherapy in Advanced Gastric Cancer

Ulas D. Bayraktar, MD

Colorectal Cancer

New Protocol: Trifluridine-Tipiracil and Panitumumab for Refractory RAS WT Colorectal Cancer

Ulas D. Bayraktar, MD

Hepatocellular Carcinoma

New Reference: Cabozantinib and Atezolizumab in HCC

Ulas D. Bayraktar, MD

Follicular Lymphoma

New Protocol: Lenalidomide-Rituximab for Untreated Follicular Lymphoma

Ulas D. Bayraktar, MD

Non-Small Cell Lung Cancer

New Indication: Perioperative Nivolumab and Chemotherapy for Stage III NSCLC

Ulas D. Bayraktar, MD

Hepatocellular Carcinoma

New Protocol: Tremelimumab and Durvalumab for HCC

Ulas D. Bayraktar, MD

Non-Small Cell Lung Cancer

New Indication: Pembrolizumab for Early-Stage NSCLC

Ulas D. Bayraktar, MD

GastroEsophageal Cancer

New Reference: Trastuzumab Deruxtecan in her2-Positive Advanced Gastroesophageal Cancer

Ulas D. Bayraktar, MD

Soft Tissue Sarcoma

New Indication: Atezolizumab for Advanced Alveolar Soft Part Sarcoma

Open-label, multicenter, phase 2 study Unresectable or metasatic ASPS Atezolizumab 1200 mg in adults (n=49) or 15 mg/kg (1200 mg max) in pediatric pts (n=3) once q21 days

GastroEsophageal Cancer

New Reference: Pembrolizumab with Chemotherapy in Advanced Gastric Cancer

Double-blind, multicenter, randomised, phase 3 study (Keynote 859) Previously untreated locally advanced/metastatic HER2 negative GEJ and gastric adenocancer Pembrolizumab + Cht (n

Colorectal Cancer

New Protocol: Trifluridine-Tipiracil and Panitumumab for Refractory RAS WT Colorectal Cancer

Phase II, multicenter (VELO) Patients with refractory RAS WT mCRC Trifluridine-tipiracil +Panitimumab (n=31) vs. Trifluridine-tipiracil (n=31)

Hepatocellular Carcinoma

New Reference: Cabozantinib and Atezolizumab in HCC

Open-label, randomised, phase 3 trial Previously untreated advanced hepatocellular carcinoma Cabozantinib 40 mg plus atezolizumab 1200 mg IV every 3 weeks (N:432), sorafenib 400 mg

Follicular Lymphoma

New Protocol: Lenalidomide-Rituximab for Untreated Follicular Lymphoma

Phase 3, open label, randomized study (RELEVANCE) Untreated grade 1-3a FL R2 (n:513) or R-chemo (n:517), followed by rituximab maintenance

Non-Small Cell Lung Cancer

New Indication: Perioperative Nivolumab and Chemotherapy for Stage III NSCLC

A Phase II , Randomized, Open-label , multicenter trial Resectable, stage IIIA or IIIB NSCLC Arm A: Nivolumab + Carboplatin + PaclitaxelS->Nivolumab (n=57) Arm B: Carboplatin +

Hepatocellular Carcinoma

New Protocol: Tremelimumab and Durvalumab for HCC

Open-label, phase 3 trial Unresectable hepatocellular carcinoma and no previous systemic treatment Tremelimumab (300 mg, one dose) plus durvalumab (1500 mg every 4 weeks; STRIDE,

Non-Small Cell Lung Cancer

New Indication: Pembrolizumab for Early-Stage NSCLC

A Phase III placebo-controlled, Randomized, Open-label trial (KEYNOTE-671) Resectable, early stage (stage II and III) NSCLC Arm A: Pembrolizumab + chemotherapyS->Pembrolizumab (

GastroEsophageal Cancer

New Reference: Trastuzumab Deruxtecan in her2-Positive Advanced Gastroesophageal Cancer

Single-arm, multicenter, phase II trial HER2 positive, unresectable or metastatic gastric or gastro-oesophageal junction cancer, progressive disease on or after first-line therapy

Our Solutions

Altai Protocol Library

Our protocol library curated since 2015 with over 1,000 protocols

Altai Oncology Suite

Our premiere, CE-marked, Windows application designed for cancer centers

Altai Oncology App

Easiest access to our protocol library on your hands

Altai Chemo Planner

Core features of Altai Oncology Suite for the solo Oncologist/Hematologist

Articles

Computerized Chemotherapy Order Entry

The Power of a Protocol Library: Standardizing Oncology Care Across Institutions

Oncology care is inherently complex — with evolving treatment regimens, biomarker-specific indications, organ-based dosing, and rapidly changing guidelines. In this landscape, consistency and clarity become essential not only for safety, but also for quality and equity. This is where a centralized protocol library becomes a game-changer …

From Protocol to Pharmacy: Ensuring Seamless Chemotherapy Order Handover

Chemotherapy isn’t just about selecting a protocol — it’s about delivering it safely, on time, and without miscommunication. This article walks through the full treatment workflow from oncologist to pharmacist to infusion nurse, and shows how Altai Oncology creates a unified, structured order that eliminates delays, errors, and manual rework.

Back to top Drag